O(On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
+14
Background: Childhood cancer survivors have a higher risk of developing malignancies later in life compared with individuals of similar age in the general population. In Spain, population-based evidence on second malignant neoplasms (SMNs) is limited. This study aimed to estimate survival following childhood cancer diagnosis and to assess the risk of SMNs in Spain. Methods: This population-based registry study used data from 12 cancer registries within the Spanish Network of Cancer Registries (REDECAN). All malignancies of sites and non-malignant central nervous system (CNS) tumors diagnosed before age 15 were included. Age-standardized incidence rates (ASIRw) for 2015–2019 were calculated. Five- and 10-year age-adjusted observed survival rates for 1990–1999 and 2000–2009 were estimated. SMN risk was assessed using standardized incidence ratios (SIRs) and excess absolute risks (EARs). Results: The ASIRw for 2015–2019 was 181.3 per million child-years. Ten-year survival increased from 71.3% in 1990–1999 to 75.5% in 2000–2009. The overall risk of developing an SMN was significantly elevated (SIR = 5.67) at 20 years. Conclusions: Although survival for childhood cancer in Spain was around 75% in 2000–2009, childhood cancer survivors remain at substantially increased risk of SMNs for at least two decades. Efforts to reduce treatment-related toxicity while maintaining survival gains are essential.
Background: Childhood cancer survivors are more likely to develop cancer in adulthood than people of similar age in the general population. In Spain, there are no popula-tion-based studies on the risk of developing second cancers in people diagnosed with childhood cancer. The main objective of this study was to present recent survival rates fol-lowing a childhood cancer diagnosis in Spain and to investigate the risk of second malig-nant neoplasms (SMNs) in people diagnosed with childhood cancer between 1990 and 2009. Methods: This population-based registry study, devised by the Spanish Network of Cancer Registries (REDECAN), collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 15 years in populations covered by 12 cancer registries of Spain. Age-standardised incidence rates (ASIRw) for the period 2015–19 were calculated per million childhood-years. Five-year and 10-year age-adjusted observed sur-vival rates, for the periods 1990-1999 and 2000–2009 were estimated. The risk of develop-ing SMNs was calculated using standardized incidence ratio (SIR), excess absolute risk (EAR). Age-specific incidence rates of SMN were also calculated. Results: During the pe-riod 2015-2019, the ASIRw was 181.3 per million child-years. The 10-year childhood sur-vival rate for both sexes combined increased from 71.3% to 75.5% between the 1990s and the 2000s. The relative risk of a SMN in people with a first childhood cancer diagnosed between 1990 and 2009 was 5.67 at 20 years after the diagnosis of the first cancer. Conclu-sion: In the 2000s, the 10-year survival rate for childhood cancer in Spain was around 75%, but survivors faced a high risk of developing a second cancer for at least 20 years af-ter their initial diagnosis. Efforts to reduce treatment-related toxicity are essential to miti-gate this long-term risk without compromising survival outcomes.